These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Transplantation; 1999 Jul 15; 68(1):55-62. PubMed ID: 10428267 [Abstract] [Full Text] [Related]
7. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group. Transplantation; 2001 Sep 27; 72(6):1024-32. PubMed ID: 11579295 [Abstract] [Full Text] [Related]
10. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C. Transplantation; 2002 May 15; 73(9 Suppl):S19-22. PubMed ID: 12023609 [No Abstract] [Full Text] [Related]
12. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Shah MB, Martin JE, Schroeder TJ, First MR. Transplant Proc; 1998 Dec 15; 30(8):4048-53. PubMed ID: 9865291 [No Abstract] [Full Text] [Related]
14. Patient management by Neoral C(2) monitoring: an international consensus statement. Levy G, Thervet E, Lake J, Uchida K, Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Transplantation; 2002 May 15; 73(9 Suppl):S12-8. PubMed ID: 12023608 [No Abstract] [Full Text] [Related]
15. Neoral dose monitoring with cyclosporine 2-hour postdose levels (C(2)) in different renal transplant patient age groups. Rosati A, Bertoni E, Zanazzi M, Di Maria L, Ciuti R, Piperno R, Moscarelli L, Biagini M, Salvadori M. Transplant Proc; 2001 May 15; 33(7-8):3106-7. PubMed ID: 11750335 [No Abstract] [Full Text] [Related]
16. Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral. Sindhi R, Shah J, Foley L, Bucsis J, Kyryliuk T, Baliga PK, Rajagopalan PR. Transplant Proc; 1998 Jun 15; 30(4):1197-8. PubMed ID: 9636485 [No Abstract] [Full Text] [Related]
17. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. Meier-Kriesche HU, Alloway R, Gaber AO, Canafax DM, Kaplan B. J Clin Pharmacol; 1999 Feb 15; 39(2):166-71. PubMed ID: 11563409 [Abstract] [Full Text] [Related]
18. Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. Schroeder TJ, Cho MJ, Pollack GM, Floc'h R, Moran HB, Levy R, Moore LW, Pouletty P. J Clin Pharmacol; 1998 Sep 15; 38(9):807-14. PubMed ID: 9753208 [Abstract] [Full Text] [Related]
19. Pharmacokinetic analysis of cyclosporine in a renal transplant recipient with congenital absence of the portal vein. Nakazawa R, Sato Y, Sasaki H, Shibagaki Y, Kimura K, Chikaraishi T. Int J Urol; 2015 Aug 15; 22(8):785-7. PubMed ID: 26041083 [Abstract] [Full Text] [Related]
20. Neoral monitoring: limitations of trough level monitoring and the potential role of limited sampling strategies. Cole EH. Transplant Proc; 2000 Nov 15; 32(7):1556-8. PubMed ID: 11119832 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]